Complement protein C5 inhibitor: Clinical Trials

1 active not recruiting, 1 withdrawn. 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	2	Active not recruiting 1, Withdrawn 1

Follow Complement protein C5 inhibitor: new trials by email Literature Review of Complement protein C5 inhibitor trials Research Report on Complement protein C5 inhibitor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder Intravenous Methylprednisolone (IVMP), Complement protein C5 inhibitor - Neuromyelitis Optica Spectrum Disorder Attack	Phase 2	Active not recruiting	Tianjin Medical University General Hospital	110	2025-09-09	2026-06-03
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder Complement protein C5 inhibitor, IVMP - Neuromyelitis Optica Spectrum Disorder Attack	Phase 2	Withdrawn	Tianjin Medical University General Hospital		2025-09-03	2025-09-10

Conditions studied

Neuromyelitis Optica (2)

Sponsors

Tianjin Medical University General Hospital (2)

Countries

China (1)